II. Indications: Inflammatory Bowel Disease
- Ulcerative Colitis
 - Crohns Disease (off-label use)
 
III. Mechanism
- 5-Aminosalicylic Acid Derivative
 - Mesalamine is the active agent of the antiinflammatory Sulfasalazine
 - Mesalamine decreases gastrointestinal inflammation via inhibition of cyclooxygenase and Prostaglandin
 - Minimal absorption and acts locally within the bowel
 
IV. Dosing: Ulcerative Colitis (Adults)
- Background
- Rectal forms are preferred for Proctitis
 - Use oral and rectal forms combined for better results where pancolitis is present
 
 - Oral
- Active disease: 2.4 to 4.8 grams/day divided 1 to 3 times daily for 6 to 8 weeks (depending on agent)
- Delzicol 800 mg orally three times daily
 - Pentasa 1 g orally four times daily (may be opened and mixed with water or applesauce)
 - Mesalamine MMX (e.g. Lialda) 2.4 to 4.8 g orally daily with meals
 - Asacol HD 1.6 g orally three times daily
 
 - Maintenance: 1.2 to 2.4 grams/day divided 1 to 3 times daily (depending on agent)
- Delzicol 800 mg orally twice daily
 - Apriso 1.5 g orally daily
 - Mesalamine MMX (e.g. Lialda) 2.4 g orally daily
 - Asacol HD 2.4 to 4.8 g/day orally divided three times daily
 
 
 - Active disease: 2.4 to 4.8 grams/day divided 1 to 3 times daily for 6 to 8 weeks (depending on agent)
 - Diazo-Bonded 5-ASA product Formulations (oral agents activated in colon)
- See Balsalazide
 - See Olsalazine
 
 - Suppository (e.g. Cantasa, for Ulcerative Proctitis)
- Active disease: 1000 mg once daily at bedtime
 - Maintenance: 500 mg once to twice daily
 
 - Enema (e.g. Rowasa 4 g in 60 ml, provides high descending colon concentrations)
- Active disease: 1 to 4 grams daily
 - Maintenance: 2-4 grams daily to every third day
 
 
V. Dosing: Child
- Indicated in age 5 years and older
 - Weight 17 to 32 kg
- Mesalamine 36 to 71 mg/kg/day (maximum 1.2 g/day)
 
 - Weight 33 to 53 kg
- Mesalamine 37 to 61 mg/kg/day (maximum 2.0 g/day)
 
 - Weight 54 to 90 kg
- Mesalamine 27 to 4 mg/kg/day (maximum 2.4 g/day)
 
 
VI. Adverse Effects
- Most common
 - Other
- Interstitial Nephritis
 - Hepatic failure (risk in preexisting liver disease)
 - Suppositories and enemas may cause rectal irritation
 - Phenylketonuria Risk (Apriso)
- Apriso contains Phenylalanine
 
 - Digoxin
- Mesalamine may decrease levels
 
 - Urine Color change
- Yellow-brown discolored urine
 
 
 
VII. Drug Interactions
- False positive Urine Metanephrines
 
VIII. Safety
- Pregnancy Category C
 - Unknown safet in Lactation
 
IX. Resources
- Mesalamine Delayed Release Tablet (DailyMed)
 - Mesalamine Delayed Release Capsule (DailyMed)
 
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
 - (2022) Treatment of Mild to Moderate Ulcerative Colitis, Presc Lett, #350406
 - (2023) Drugs for Inflammatory Bowel Disease, Med Lett Drug Ther 65: 105-12
 - Adams (2013) Am Fam Physician 87(10): 699-705 [PubMed]
 - Adams (2022) Am Fam Physician 105(4): 406-11 [PubMed]
 - Kornbluth (2010) Am J Gastroenterol 105(3): 501-23 [PubMed]
 
Images: Related links to external sites (from Bing)
Related Studies
| mesalamine (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| MESALAMINE 1,000 MG SUPP | Generic | $2.21 each | 
| MESALAMINE 4 GM/60 ML ENEMA | Generic | $0.13 per ml | 
| MESALAMINE 4 GM/60 ML KIT | Generic | $116.13 each | 
| MESALAMINE 800 MG DR TABLET | Generic | $5.99 each | 
| MESALAMINE DR 1.2 GM TABLET | Generic | $2.22 each | 
| MESALAMINE DR 400 MG CAPSULE | Generic | $2.53 each | 
| MESALAMINE ER 0.375 GRAM CAP | Generic | $0.89 each | 
| MESALAMINE ER 500 MG CAPSULE | Generic | $4.64 each | 
| pentasa (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| PENTASA 250 MG CAPSULE | $2.91 each | |
| PENTASA 500 MG CAPSULE | Generic | $4.64 each | 
| lialda (on 6/14/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| LIALDA DR 1.2 GM TABLET | Generic | $2.05 each | 
| delzicol (on 7/19/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| DELZICOL DR 400 MG CAPSULE | Generic | $2.11 each |